|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: ZNF10 |
Gene summary for ZNF10 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | ZNF10 | Gene ID | 7556 |
| Gene name | zinc finger protein 10 | |
| Gene Alias | KOX1 | |
| Cytomap | 12q24.33 | |
| Gene Type | protein-coding | GO ID | GO:0000122 | UniProtAcc | P21506 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 7556 | ZNF10 | LZE4T | Human | Esophagus | ESCC | 6.35e-07 | 2.44e-01 | 0.0811 |
| 7556 | ZNF10 | LZE7T | Human | Esophagus | ESCC | 3.99e-03 | 2.73e-01 | 0.0667 |
| 7556 | ZNF10 | LZE20T | Human | Esophagus | ESCC | 2.48e-02 | 1.30e-01 | 0.0662 |
| 7556 | ZNF10 | LZE21D1 | Human | Esophagus | HGIN | 2.59e-02 | 1.83e-01 | 0.0632 |
| 7556 | ZNF10 | LZE22T | Human | Esophagus | ESCC | 4.16e-04 | 2.06e-01 | 0.068 |
| 7556 | ZNF10 | LZE24T | Human | Esophagus | ESCC | 1.02e-12 | 2.53e-01 | 0.0596 |
| 7556 | ZNF10 | LZE21T | Human | Esophagus | ESCC | 4.65e-02 | 2.09e-01 | 0.0655 |
| 7556 | ZNF10 | P1T-E | Human | Esophagus | ESCC | 2.04e-08 | 4.02e-01 | 0.0875 |
| 7556 | ZNF10 | P2T-E | Human | Esophagus | ESCC | 1.10e-45 | 7.76e-01 | 0.1177 |
| 7556 | ZNF10 | P4T-E | Human | Esophagus | ESCC | 5.07e-19 | 5.04e-01 | 0.1323 |
| 7556 | ZNF10 | P5T-E | Human | Esophagus | ESCC | 1.95e-13 | 3.20e-01 | 0.1327 |
| 7556 | ZNF10 | P8T-E | Human | Esophagus | ESCC | 5.29e-14 | 2.44e-01 | 0.0889 |
| 7556 | ZNF10 | P10T-E | Human | Esophagus | ESCC | 2.12e-12 | 2.39e-01 | 0.116 |
| 7556 | ZNF10 | P11T-E | Human | Esophagus | ESCC | 1.22e-10 | 6.39e-01 | 0.1426 |
| 7556 | ZNF10 | P12T-E | Human | Esophagus | ESCC | 4.63e-21 | 4.06e-01 | 0.1122 |
| 7556 | ZNF10 | P15T-E | Human | Esophagus | ESCC | 2.44e-11 | 1.69e-01 | 0.1149 |
| 7556 | ZNF10 | P16T-E | Human | Esophagus | ESCC | 1.08e-24 | 4.41e-01 | 0.1153 |
| 7556 | ZNF10 | P17T-E | Human | Esophagus | ESCC | 1.73e-04 | 1.29e-01 | 0.1278 |
| 7556 | ZNF10 | P21T-E | Human | Esophagus | ESCC | 4.18e-10 | 2.27e-01 | 0.1617 |
| 7556 | ZNF10 | P22T-E | Human | Esophagus | ESCC | 2.15e-17 | 3.55e-01 | 0.1236 |
| Page: 1 2 3 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0032868 | Colorectum | AD | response to insulin | 91/3918 | 264/18723 | 2.02e-07 | 8.48e-06 | 91 |
| GO:1901653 | Colorectum | AD | cellular response to peptide | 114/3918 | 359/18723 | 8.32e-07 | 2.88e-05 | 114 |
| GO:0032869 | Colorectum | AD | cellular response to insulin stimulus | 72/3918 | 203/18723 | 1.10e-06 | 3.68e-05 | 72 |
| GO:0071375 | Colorectum | AD | cellular response to peptide hormone stimulus | 95/3918 | 290/18723 | 1.50e-06 | 4.66e-05 | 95 |
| GO:0043434 | Colorectum | AD | response to peptide hormone | 126/3918 | 414/18723 | 2.70e-06 | 7.86e-05 | 126 |
| GO:00434343 | Colorectum | FAP | response to peptide hormone | 100/2622 | 414/18723 | 1.74e-08 | 1.84e-06 | 100 |
| GO:19016533 | Colorectum | FAP | cellular response to peptide | 89/2622 | 359/18723 | 2.93e-08 | 2.64e-06 | 89 |
| GO:00713753 | Colorectum | FAP | cellular response to peptide hormone stimulus | 75/2622 | 290/18723 | 5.60e-08 | 4.29e-06 | 75 |
| GO:00328683 | Colorectum | FAP | response to insulin | 68/2622 | 264/18723 | 2.71e-07 | 1.55e-05 | 68 |
| GO:00328693 | Colorectum | FAP | cellular response to insulin stimulus | 54/2622 | 203/18723 | 1.54e-06 | 6.59e-05 | 54 |
| GO:0008286 | Colorectum | FAP | insulin receptor signaling pathway | 28/2622 | 116/18723 | 2.37e-03 | 1.89e-02 | 28 |
| GO:00434344 | Colorectum | CRC | response to peptide hormone | 76/2078 | 414/18723 | 6.67e-06 | 2.56e-04 | 76 |
| GO:00328684 | Colorectum | CRC | response to insulin | 53/2078 | 264/18723 | 1.30e-05 | 4.17e-04 | 53 |
| GO:00328694 | Colorectum | CRC | cellular response to insulin stimulus | 42/2078 | 203/18723 | 4.79e-05 | 1.12e-03 | 42 |
| GO:00713754 | Colorectum | CRC | cellular response to peptide hormone stimulus | 55/2078 | 290/18723 | 4.82e-05 | 1.12e-03 | 55 |
| GO:19016534 | Colorectum | CRC | cellular response to peptide | 64/2078 | 359/18723 | 8.54e-05 | 1.75e-03 | 64 |
| GO:00082861 | Colorectum | CRC | insulin receptor signaling pathway | 23/2078 | 116/18723 | 4.02e-03 | 3.33e-02 | 23 |
| GO:190165319 | Esophagus | ESCC | cellular response to peptide | 208/8552 | 359/18723 | 1.68e-06 | 2.01e-05 | 208 |
| GO:0043434111 | Esophagus | ESCC | response to peptide hormone | 234/8552 | 414/18723 | 4.93e-06 | 5.21e-05 | 234 |
| GO:003286918 | Esophagus | ESCC | cellular response to insulin stimulus | 124/8552 | 203/18723 | 6.63e-06 | 6.75e-05 | 124 |
| Page: 1 2 3 4 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| ZNF10 | SNV | Missense_Mutation | c.1463N>A | p.Pro488Gln | p.P488Q | P21506 | protein_coding | deleterious(0) | probably_damaging(0.923) | TCGA-A8-A09Z-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| ZNF10 | SNV | Missense_Mutation | novel | c.749N>A | p.Gly250Asp | p.G250D | P21506 | protein_coding | tolerated(0.21) | benign(0.021) | TCGA-BH-A0HY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | taxotere | CR |
| ZNF10 | SNV | Missense_Mutation | c.1173N>G | p.His391Gln | p.H391Q | P21506 | protein_coding | tolerated(0.47) | benign(0.005) | TCGA-D8-A1XY-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | tamoxiphen | SD | |
| ZNF10 | insertion | Frame_Shift_Ins | novel | c.1644_1645insACATACATCCTAGCATTCTCAC | p.Gln549ThrfsTer15 | p.Q549Tfs*15 | P21506 | protein_coding | TCGA-A8-A0A1-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
| ZNF10 | insertion | In_Frame_Ins | novel | c.517_518insACA | p.Cys173delinsTyrSer | p.C173delinsYS | P21506 | protein_coding | TCGA-AN-A0FN-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| ZNF10 | insertion | Nonsense_Mutation | novel | c.518_519insATAAAGC | p.Cys173Ter | p.C173* | P21506 | protein_coding | TCGA-AN-A0FN-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| ZNF10 | deletion | Frame_Shift_Del | c.1343delN | p.Tyr449IlefsTer85 | p.Y449Ifs*85 | P21506 | protein_coding | TCGA-E2-A15A-06 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | SD | |||
| ZNF10 | deletion | Frame_Shift_Del | novel | c.476_488delNNNNNNNNNNNNN | p.Gln160LeufsTer16 | p.Q160Lfs*16 | P21506 | protein_coding | TCGA-EW-A423-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | anastrozole | SD | ||
| ZNF10 | SNV | Missense_Mutation | c.1225N>A | p.Glu409Lys | p.E409K | P21506 | protein_coding | tolerated(0.16) | benign(0.025) | TCGA-IR-A3LA-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| ZNF10 | SNV | Missense_Mutation | novel | c.137N>G | p.Asn46Ser | p.N46S | P21506 | protein_coding | tolerated(0.07) | benign(0.361) | TCGA-5M-AAT6-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Unknown | Unknown | PD |
| Page: 1 2 3 4 5 6 7 8 9 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |